Introduction to the main functions and effects of Pemetinib/Dabotan Tablets

Pemigatinib(Pemigatinib) is a new oral targeted drug that has gradually attracted clinical attention in recent years. Its research and development logic is based on the precise treatment concept of molecular typing, which is especially suitable for tumor patients with specific molecular abnormalities. When traditional treatment methods are limited and ineffective, the emergence of pemetinib provides a new option for some patients with cholangiocarcinoma, bladder cancer, etc. Therefore, its efficacy and role have become the focus of clinical and patient discussions.

From a mechanism of action perspective, pemetinib is a selectiveFGFR (fibroblast growth factor receptor) kinase inhibitor. The FGFR pathway is involved in cell differentiation, angiogenesis, and tissue repair in normal cells. However, in some tumors, due to genetic abnormalities such as FGFR2 fusion or rearrangement, the signaling pathway continues to be abnormally activated, leading to unlimited cell proliferation and evasion of apoptosis. Pemetinib cuts off this abnormal signal by inhibiting the activity of receptors such as FGFR1, FGFR2 and FGFR3, thereby inhibiting the growth of tumor cells and achieving the purpose of controlling the disease. Different from the "wide net" of traditional chemotherapy, pemetinib is a precise attack at the molecular level, so the target is clearer and the pharmacological effects are more targeted.

In terms of clinical efficacy, pemetinib was first approved overseas for patients with FGFR2 fusion or rearrangement cholangiocarcinoma (CCA) . The establishment of this indication has given many patients who have received first-line treatment but whose disease has progressed a new option. With the expansion of its applications, it has gradually been studied in some fields such as bladder cancer and osteosarcoma. This potential across cancer types is the charm of targeted drugs. Since it determines whether to take medication by detecting the patient's gene mutation status, patients usually need to undergo molecular testing before receiving treatment to confirm whether there is a corresponding FGFR abnormality, so as to screen out the truly suitable people.

Reference materials:https://go.drugbank.com/drugs/DB15102